GREAT NECK, N.Y., March 12, 2018 -- One Liberty Properties, Inc. (NYSE:OLP) today announced that its Board of Directors declared a quarterly dividend on the Company’s common stock of $0.45 per share. The dividend is payable April 6, 2018 to stockholders of record at the close of business on March 27, 2018.
One Liberty is a self-administered and self-managed real estate investment trust incorporated in Maryland in 1982. The Company acquires, owns and manages a geographically diversified portfolio consisting primarily of industrial, retail, restaurant, health and fitness and theater properties. Many of these properties are subject to long-term net leases under which the tenant is typically responsible for real estate taxes, insurance and ordinary maintenance and repairs.
Contact:
One Liberty Properties
Investor Relations
Phone: (516) 466-3100
www.onelibertyproperties.com


Amazon Explores AI Content Marketplace With Media Publishers
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Anta Sports Expands Global Footprint With Strategic Puma Stake
Washington Post Publisher Will Lewis Steps Down After Layoffs
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 



